When psoriasis manifests in palmoplantar and intertriginous regions or on the nails, this often poses a therapeutic challenge. Several recently presented analyses on the effects of anti-IL-23p19 antibodies currently approved for psoriasis focused on patient populations with infestation of these difficult-to-treat body regions.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Pain and autism
Hurdles to pain treatment for autistic patients
- Pathophysiological mechanisms and therapeutic perspectives
Metabolic syndrome in patients with schizophrenia
- Hand eczema: from diagnosis to treatment
Implementing sustainable, stage-appropriate measures
- Cystic fibrosis
Small spray – big footprint
- From symptom to diagnosis
Abdominal pain – Gastric outlet stenosis
- When the bones become more fragile: “Case Finding”
Fracture risk reduction in osteoporosis
- Biologics for plaque psoriasis
What increases the chance of a sustained remission?
- Findings from the ALS Symposium 2024 in Montreal